Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.: The Laryngoscope

Ester Orlandi; Stefano Cavalieri; Roberta Granata; Piero Nicolai; Paolo Castelnuovo; Cesare Piazza; Alberto Schreiber; Mario Turri-Zanoni; Pasquale Quattrone; Rosalba Miceli; Gabriele Infante; Fausto Sessa; Carla Facco; Giuseppina Calareso; Nicola Alessandro Iacovelli; Davide Mattavelli; Alberto Paderno; Carlo Resteghini; Laura Deborah Locati; Lisa Licitra; Paolo Bossi

doi:10.1002/lary.28202

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. The Laryngoscope

Ester Orlandi, Stefano Cavalieri, Roberta Granata, Piero Nicolai, Paolo Castelnuovo, Cesare Piazza, Alberto Schreiber, Mario Turri-Zanoni, Pasquale Quattrone, Rosalba Miceli, Gabriele Infante, Fausto Sessa, Carla Facco, Giuseppina Calareso, Nicola Alessandro Iacovelli, Davide Mattavelli, Alberto Paderno, Carlo Resteghini, Laura Deborah Locati, Lisa LicitraPaolo Bossi

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. METHODS: We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum-based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. RESULTS: We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease-free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P

Original language	English
Pages (from-to)	857-865
Number of pages	9
Journal	Laryngoscope
Volume	130
Issue number	4
DOIs	https://doi.org/10.1002/lary.28202
Publication status	Published - 2020

Keywords

Adult
Female
Humans
Male
Middle Aged
Combined Modality Therapy
Neoplasm Staging
Adolescent
Aged
Prognosis
*radiation
*surgery
Salvage Therapy
*induction chemotherapy
*multimodal treatment
*Sinonasal cancer
Palliative Care
Paranasal Sinus Neoplasms/mortality/pathology/*therapy

Access to Document

10.1002/lary.28202

Cite this

Orlandi, E., Cavalieri, S., Granata, R., Nicolai, P., Castelnuovo, P., Piazza, C., Schreiber, A., Turri-Zanoni, M., Quattrone, P., Miceli, R., Infante, G., Sessa, F., Facco, C., Calareso, G., Iacovelli, N. A., Mattavelli, D., Paderno, A., Resteghini, C., Locati, L. D., ... Bossi, P. (2020). Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. The Laryngoscope. Laryngoscope, 130(4), 857-865. https://doi.org/10.1002/lary.28202

Orlandi, E, Cavalieri, S, Granata, R, Nicolai, P, Castelnuovo, P, Piazza, C, Schreiber, A, Turri-Zanoni, M, Quattrone, P , Miceli, R, Infante, G, Sessa, F, Facco, C, Calareso, G , Iacovelli, NA, Mattavelli, D, Paderno, A, Resteghini, C, Locati, LD, Licitra, L & Bossi, P 2020, 'Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. The Laryngoscope', Laryngoscope, vol. 130, no. 4, pp. 857-865. https://doi.org/10.1002/lary.28202

@article{648895d9b3f44c9b8cee32a6af1e2566,

title = "Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.: The Laryngoscope",

abstract = "OBJECTIVE: Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. METHODS: We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum-based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. RESULTS: We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease-free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P ",

keywords = "Adult, Female, Humans, Male, Middle Aged, Combined Modality Therapy, Neoplasm Staging, Adolescent, Aged, Prognosis, *radiation, *surgery, Salvage Therapy, *induction chemotherapy, *multimodal treatment, *Sinonasal cancer, Palliative Care, Paranasal Sinus Neoplasms/mortality/pathology/*therapy",

author = "Ester Orlandi and Stefano Cavalieri and Roberta Granata and Piero Nicolai and Paolo Castelnuovo and Cesare Piazza and Alberto Schreiber and Mario Turri-Zanoni and Pasquale Quattrone and Rosalba Miceli and Gabriele Infante and Fausto Sessa and Carla Facco and Giuseppina Calareso and Iacovelli, {Nicola Alessandro} and Davide Mattavelli and Alberto Paderno and Carlo Resteghini and Locati, {Laura Deborah} and Lisa Licitra and Paolo Bossi",

year = "2020",

doi = "10.1002/lary.28202",

language = "English",

volume = "130",

pages = "857--865",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.

T2 - The Laryngoscope

AU - Orlandi, Ester

AU - Cavalieri, Stefano

AU - Granata, Roberta

AU - Nicolai, Piero

AU - Castelnuovo, Paolo

AU - Piazza, Cesare

AU - Schreiber, Alberto

AU - Turri-Zanoni, Mario

AU - Quattrone, Pasquale

AU - Miceli, Rosalba

AU - Infante, Gabriele

AU - Sessa, Fausto

AU - Facco, Carla

AU - Calareso, Giuseppina

AU - Iacovelli, Nicola Alessandro

AU - Mattavelli, Davide

AU - Paderno, Alberto

AU - Resteghini, Carlo

AU - Locati, Laura Deborah

AU - Licitra, Lisa

AU - Bossi, Paolo

PY - 2020

Y1 - 2020

N2 - OBJECTIVE: Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. METHODS: We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum-based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. RESULTS: We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease-free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P

AB - OBJECTIVE: Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. METHODS: We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum-based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. RESULTS: We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease-free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P

KW - Adult

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Combined Modality Therapy

KW - Neoplasm Staging

KW - Adolescent

KW - Aged

KW - Prognosis

KW - radiation

KW - surgery

KW - Salvage Therapy

KW - induction chemotherapy

KW - multimodal treatment

KW - Sinonasal cancer

KW - Palliative Care

KW - Paranasal Sinus Neoplasms/mortality/pathology/therapy

U2 - 10.1002/lary.28202

DO - 10.1002/lary.28202

M3 - Article

SN - 0023-852X

VL - 130

SP - 857

EP - 865

JO - Laryngoscope

JF - Laryngoscope

IS - 4

ER -

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. The Laryngoscope

Abstract

Keywords

Access to Document

Fingerprint

Cite this